In the field of cardiovascular disease, the correlation between clopidogrel treatment of patients with CYP2C19 LoFA and poor prognosis has been widely confirmed [5–7], and Claassens et al. found that the early use of P2Y12 inhibitors under the guidance of CYP2C19 genotype to treat patients who undergoing primary percutaneous coronary intervention could reduce thrombotic events and the risk of bleeding compared with standard treatment [18]. The gene discussed is CYP2C19; the disease is cardiovascular disorder.